RxDoctor Payments Data

Richard Eichel, MD

Gastroenterology · Little Silver, NJNPI 1104817576

Payments from drug & device makers

$3,851in general payments, 2019–2025

Across 283 payments — averaging $13.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$569
  • Takeda Pharmaceuticals U.S.A., Inc.$330
  • Ironwood Pharmaceuticals, Inc$269
  • Bristol Myers Squibb$254
  • Johnson & Johnson$239
  • plus $835 from 15 others

What the payments were for

  • Food & beverage$3,75898%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,851 in reported general payments places this provider in the 60th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$123,352
Medicare patients
224
Services billed
852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase25$122,172
TrulancePlecanatide26$13,963
LinzessLinaclotide23$12,888
VoqueznaVonoprazan Fumarate15$12,707
Mesalamine16$8,952
ClenpiqSod Picosulf/Mag Ox/Citric Ac41$7,020
Alosetron Hcl12$6,844
Sucralfate41$5,443
Mesalamine DrMesalamine12$5,305
Pantoprazole Sodium207$3,118
Lubiprostone19$1,520
Famotidine112$1,295
Esomeprazole Magnesium29$1,088
Dicyclomine Hcl69$952
Lansoprazole13$912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,354$135,06048 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$569$13,96326 claims
Phathom Pharmaceuticals, Inc.Voquezna$53$12,70715 claims
Ferring Pharmaceuticals Inc.Clenpiq$26$7,02041 claims
SandozLansoprazole$16$91213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Little Silver

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →